CoChat

TGF-beta1 regulates human brain pericyte inflammatory processes involved in neurovasculature function

Open access

The DOI matches its Crossref record; 110 of the 111 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Transforming growth factor beta 1 (TGFβ1) is strongly induced following brain injury and polarises microglia to an anti-inflammatory phenotype. Augmentation of TGFβ1 responses may therefore be beneficial in preventing inflammation in neurological disorders including stroke and neurodegenerative diseases. However, several other cell types display immunogenic potential and identifying the effect of TGFβ1 on these cells is required to more fully understand its effects on brain inflammation. Pericytes are multifunctional cells which ensheath the brain vasculature and have garnered recent attention with respect to their immunomodulatory potential. Here, we sought to investigate the inflammatory phenotype adopted by TGFβ1-stimulated human brain pericytes. METHODS: Microarray analysis was performed to examine transcriptome-wide changes in TGFβ1-stimulated pericytes, and results were validated by qRT-PCR and cytometric bead arrays. Flow cytometry, immunocytochemistry and LDH/Alamar Blue® viability assays were utilised to examine phagocytic capacity of human brain pericytes, transcription factor modulation and pericyte health. RESULTS: TGFβ1 treatment of primary human brain pericytes induced the expression of several inflammatory-related genes (NOX4, COX2, IL6 and MMP2) and attenuated others (IL8, CX3CL1, MCP1 and VCAM1). A synergistic induction of IL-6 was seen with IL-1β/TGFβ1 treatment whilst TGFβ1 attenuated the IL-1β-induced expression of CX3CL1, MCP-1 and sVCAM-1. TGFβ1 was found to signal through SMAD2/3 transcription factors but did not modify nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB) translocation. Furthermore, TGFβ1 attenuated the phagocytic ability of pericytes, possibly through downregulation of the scavenger receptors CD36, CD47 and CD68. Whilst TGFβ did decrease pericyte number, this was due to a reduction in proliferation, not apoptotic death or compromised cell viability. CONCLUSIONS: TGFβ1 attenuated pericyte expression of key chemokines and adhesion molecules involved in CNS leukocyte trafficking and the modulation of microglial function, as well as reduced the phagocytic ability of pericytes. However, TGFβ1 also enhanced the expression of classical pro-inflammatory cytokines and enzymes which can disrupt BBB functioning, suggesting that pericytes adopt a phenotype which is neither solely pro- nor anti-inflammatory. Whilst the effects of pericyte modulation by TGFβ1 in vivo are difficult to infer, the reduction in pericyte proliferation together with the elevated IL-6, MMP-2 and NOX4 and reduced phagocytosis suggests a detrimental action of TGFβ1 on neurovasculature.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12974-016-0503-0

Cites

110 of 110 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 TGFβ1 modifies inflammatory gene expression in human brain pericytes. Primary human brain pericytes were treated with vehicle (1 mM citric acid, pH 3 with 0.1 % BSA) or 10 ng/mL TGFβ1 for 72 h. RNA was extracted and expression of inflammation-related genes determined by microarray (a). Changes in gene expression (NOX4 (b), COX2 (c), MMP2 (d), IL6 (e), IL8 (f), CX3CL1 (g), MCP1 (h) and VCAM1 (i)) were confirmed by qRT-PCR from three independent experiments with 0–72 h treatments with 10 ng/mL TGFβ1. *p < 0.05, **p < 0.01, ***p < 0.001 versus 0 h time point (ANOVA)
Fig. 1 TGFβ1 modifies inflammatory gene expression in human brain pericytes. Primary human brain pericytes were treated with vehicle (1 mM citric acid, pH 3 with 0.1 % BSA) or 10 ng/mL TGFβ1 for 72 h. RNA was extracted and expression of inflammation-related genes determined by microarray (a). Changes in gene expression (NOX4 (b), COX2 (c), MMP2 (d), IL6 (e), IL8 (f), CX3CL1 (g), MCP1 (h) and VCAM1 (i)) were confirmed by qRT-PCR from three independent experiments with 0–72 h treatments with 10 ng/mL TGFβ1. *p < 0.05, **p < 0.01, ***p < 0.001 versus 0 h time point (ANOVA)CC BY · PubMed Central
Fig. 2 TGFβ1 modifies inflammatory protein secretion in human brain pericytes. Primary human brain pericytes were treated with vehicle (1 mM citric acid, pH 3 with 0.1 % BSA) or 10 ng/mL TGFβ1 for 0–72 h, and conditioned media was collected. Concentration of secreted proteins (sVCAM-1 (a), CX3CL1 (b), MCP-1 (c), IL-8 (d) and IL-6 (e)) was determined by a multiplex cytometric bead array. One representative experiment (N = 4 wells) from three independent experiments is shown. *p < 0.05, **p < 0.01, ***p < 0.001 versus vehicle control at each time point (two-way ANOVA)
Fig. 2 TGFβ1 modifies inflammatory protein secretion in human brain pericytes. Primary human brain pericytes were treated with vehicle (1 mM citric acid, pH 3 with 0.1 % BSA) or 10 ng/mL TGFβ1 for 0–72 h, and conditioned media was collected. Concentration of secreted proteins (sVCAM-1 (a), CX3CL1 (b), MCP-1 (c), IL-8 (d) and IL-6 (e)) was determined by a multiplex cytometric bead array. One representative experiment (N = 4 wells) from three independent experiments is shown. *p < 0.05, **p < 0.01, ***p < 0.001 versus vehicle control at each time point (two-way ANOVA)CC BY · PubMed Central
Fig. 3 Synergistic and preventative effects of TGFβ1 on IL-1β-induced inflammatory protein secretion. Primary human brain pericytes were treated with vehicle (1 mM citric acid, pH 3 with 0.1 % BSA) or 10 ng/mL TGFβ1 for 24 h followed by a further 24 h in the presence of 10 ng/mL IL-1β or vehicle (0.1 % BSA in PBS). Conditioned media was collected and the concentration of secreted proteins (sVCAM-1 (a), CX3CL1 (b), MCP-1 (c), IL-8 (d) and IL-6 (e)) was determined by a multiplex cytometric bead array. One representative experiment (N = 4 wells) from three independent experiments is shown. ***p < 0.001 (ANOVA)
Fig. 3 Synergistic and preventative effects of TGFβ1 on IL-1β-induced inflammatory protein secretion. Primary human brain pericytes were treated with vehicle (1 mM citric acid, pH 3 with 0.1 % BSA) or 10 ng/mL TGFβ1 for 24 h followed by a further 24 h in the presence of 10 ng/mL IL-1β or vehicle (0.1 % BSA in PBS). Conditioned media was collected and the concentration of secreted proteins (sVCAM-1 (a), CX3CL1 (b), MCP-1 (c), IL-8 (d) and IL-6 (e)) was determined by a multiplex cytometric bead array. One representative experiment (N = 4 wells) from three independent experiments is shown. ***p < 0.001 (ANOVA)CC BY · PubMed Central
Fig. 4 TGFβ1 signals through SMAD2/3 transcription factors but does not affect NF-kB translocation. Primary human brain pericytes were treated for 0–48 h with combinations of vehicle (1 mM citric acid, pH 3 with 0.1 % BSA), 10 ng/mL TGFβ1 and 10 ng/mL IL-1β. Cells were fixed and immunostained for NF-kB p65 and SMAD2/3. Representative images at 2 h are shown (a). The intensity of nuclear NF-kB (b) and nuclear SMAD2/3 (c) was determined by automated image analysis from four independent experiments. ***p < 0.001 versus vehicle control at each time point (two-way ANOVA). Scale bar = 50 μm
Fig. 4 TGFβ1 signals through SMAD2/3 transcription factors but does not affect NF-kB translocation. Primary human brain pericytes were treated for 0–48 h with combinations of vehicle (1 mM citric acid, pH 3 with 0.1 % BSA), 10 ng/mL TGFβ1 and 10 ng/mL IL-1β. Cells were fixed and immunostained for NF-kB p65 and SMAD2/3. Representative images at 2 h are shown (a). The intensity of nuclear NF-kB (b) and nuclear SMAD2/3 (c) was determined by automated image analysis from four independent experiments. ***p < 0.001 versus vehicle control at each time point (two-way ANOVA). Scale bar = 50 μmCC BY · PubMed Central
Fig. 5 TGFβ1 attenuates phagocytosis by pericytes. Pericytes were treated for 24 h with 0–10 ng/mL TGFβ1 in 1 mM citric acid, pH 3 with 0.1 % BSA, followed by a further 24 h in the presence or absence of a 1:1000 dilution of fluorescent latex beads. Cells were fixed and nuclei counterstained with DRAQ5. Representative images for vehicle and 10 ng/mL TGFβ1 treatments are shown (a). The percentage of phagocytic pericytes was determined by automated image analysis from five independent experiments (b). Confocal microscopy of pericytes plated on glass coverslips, incubated for 24 h with a 1:10,000 dilution of fluorescent beads and immunostained with PDGFRβ confirmed internalisation of beads (c). Pericytes were treated for 24 h with 0–10 ng/mL TGFβ1 in 1 mM citric acid, pH 3 with 0.1 % BSA. For an additional two hours cells were incubated in the presence or absence of a 1:1000 dilution of fluorescent latex beads. Phagocytosis was determined by flow cytometry. One representative plot is shown (d) and the mean fluorescent intensity (MFI) of five independent experiments was determined (e). *p < 0.05, **p < 0.01, ***p < 0.001 versus vehicle control (ANOVA). Scale bar = 50 μm
Fig. 5 TGFβ1 attenuates phagocytosis by pericytes. Pericytes were treated for 24 h with 0–10 ng/mL TGFβ1 in 1 mM citric acid, pH 3 with 0.1 % BSA, followed by a further 24 h in the presence or absence of a 1:1000 dilution of fluorescent latex beads. Cells were fixed and nuclei counterstained with DRAQ5. Representative images for vehicle and 10 ng/mL TGFβ1 treatments are shown (a). The percentage of phagocytic pericytes was determined by automated image analysis from five independent experiments (b). Confocal microscopy of pericytes plated on glass coverslips, incubated for 24 h with a 1:10,000 dilution of fluorescent beads and immunostained with PDGFRβ confirmed internalisation of beads (c). Pericytes were treated for 24 h with 0–10 ng/mL TGFβ1 in 1 mM citric acid, pH 3 with 0.1 % BSA. For an additional two hours cells were incubated in the presence or absence of a 1:1000 dilution of fluorescent latex beads. Phagocytosis was determined by flow cytometry. One representative plot is shown (d) and the mean fluorescent intensity (MFI) of five independent experiments was determined (e). *p < 0.05, **p < 0.01, ***p < 0.001 versus vehicle control (ANOVA). Scale bar = 50 μmCC BY · PubMed Central
Fig. 6 TGFβ1 reduces gene expression of scavenger receptors. Primary human brain pericytes were treated with vehicle (1 mM citric acid, pH 3 with 0.1 % BSA) or 10 ng/mL TGFβ1 for 24 h. RNA was extracted and expression of CD36 (a), CD68 (b) and CD47 (c) and determined by qRT-PCR from three independent experiments. *p < 0.05, ***p < 0.001 versus vehicle control (Student’s t test)
Fig. 6 TGFβ1 reduces gene expression of scavenger receptors. Primary human brain pericytes were treated with vehicle (1 mM citric acid, pH 3 with 0.1 % BSA) or 10 ng/mL TGFβ1 for 24 h. RNA was extracted and expression of CD36 (a), CD68 (b) and CD47 (c) and determined by qRT-PCR from three independent experiments. *p < 0.05, ***p < 0.001 versus vehicle control (Student’s t test)CC BY · PubMed Central
Fig. 7 TGFβ1 decreases pericyte proliferation but does not affect their viability. Primary human brain pericytes were treated with vehicle (1 mM citric acid, pH 3 with 0.1 % BSA) or 10 ng/mL TGFβ1 for 0–72 h. Cells were fixed and immunostained for cleaved caspase 3 (CC3). Nuclei were counterstained with Hoechst. Cells treated for 24 h with 50 nM okadaic acid (OA) were used as a positive control. Representative images from the 24 h time point are shown (a). The percentage of CC3 positive cells was determined by automated image analysis from three independent experiments (b). Primary human brain pericytes were treated with vehicle (1 mM citric acid, pH 3 with 0.1 % BSA) or 10 ng/mL TGFβ1 for 0–72 h. For the final 24 h, cells were incubated with 10 μM EdU. Cells were fixed, EdU visualised and nuclei counterstained with Hoechst. Representative images from the 72-h time point are shown (c). The percentage of EdU positive cells (d), and the number of cells/field of view was determined by automated image analysis from three independent experiments (e). Primary human brain pericytes were treated with vehicle (1 mM citric acid, pH 3 with 0.1 % BSA) or 10 ng/mL TGFβ1 for 0–72 h. Cytotoxicity was determined from three independent experiments by an LDH release assay using cells lysed with DMEM/F12 containing 1 % Triton-X 100 as a positive control (f). Viability was determined from three independent experiments by a two hour treatment with Alamar Blue (g). *p < 0.05, **p < 0.01, ***p < 0.001 versus vehicle control for each time point (two-way ANOVA). Scale bar = 50 μm
Fig. 7 TGFβ1 decreases pericyte proliferation but does not affect their viability. Primary human brain pericytes were treated with vehicle (1 mM citric acid, pH 3 with 0.1 % BSA) or 10 ng/mL TGFβ1 for 0–72 h. Cells were fixed and immunostained for cleaved caspase 3 (CC3). Nuclei were counterstained with Hoechst. Cells treated for 24 h with 50 nM okadaic acid (OA) were used as a positive control. Representative images from the 24 h time point are shown (a). The percentage of CC3 positive cells was determined by automated image analysis from three independent experiments (b). Primary human brain pericytes were treated with vehicle (1 mM citric acid, pH 3 with 0.1 % BSA) or 10 ng/mL TGFβ1 for 0–72 h. For the final 24 h, cells were incubated with 10 μM EdU. Cells were fixed, EdU visualised and nuclei counterstained with Hoechst. Representative images from the 72-h time point are shown (c). The percentage of EdU positive cells (d), and the number of cells/field of view was determined by automated image analysis from three independent experiments (e). Primary human brain pericytes were treated with vehicle (1 mM citric acid, pH 3 with 0.1 % BSA) or 10 ng/mL TGFβ1 for 0–72 h. Cytotoxicity was determined from three independent experiments by an LDH release assay using cells lysed with DMEM/F12 containing 1 % Triton-X 100 as a positive control (f). Viability was determined from three independent experiments by a two hour treatment with Alamar Blue (g). *p < 0.05, **p < 0.01, ***p < 0.001 versus vehicle control for each time point (two-way ANOVA). Scale bar = 50 μmCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 110 references

Cited by

See all 201

Metadata

Authors
Rustenhoven, J., Aalderink, M., Scotter, E. L., Oldfield, R. L., Bergin, P. S., Mee, E. W., Graham, E. S., Faull, R. L. M., Curtis, M. A., Park, T. I.-H., & Dragunow, M.
Affiliations
University of Auckland (NZ)
Corresponding author
Dragunow, Mike
Venue
Journal of Neuroinflammation
Published
2016-02-11
Volume
13
Issue
1
Pages
37-37
ISSN
1742-2094 (ISSN-L)
OpenAlex
W2280695772
Cited by
201
References
111
Citations by year
2026: 9 · 2025: 22 · 2024: 35 · 2023: 23 · 2022: 24 · 2021: 17 · 2020: 13 · 2019: 18 · 2018: 18 · 2017: 17 · 2016: 5
FWCI
10.59
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • Journal of Neuroinflammation (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
  • Hugh Green Foundation
  • Neurological Foundation of New Zealand
  • Health Research Council of New Zealand
Topics
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
  • Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
Keywords
TGF-β1, brain pericytes, neuroinflammation, blood-brain barrier, interleukin-6, IL-1β, Smad2/3 signaling, phagocytosis, scavenger receptors, CD36, CD47, CD68, chemokines, MMP-2, cyclooxygenase-2, NOX4
MeSH terms
NADPH Oxidase 4, Brain, Cell Survival, Gene Expression Regulation, Humans, Phagocytes, Time Factors, Signal Transduction, Cytokines, NF-kappa B, Culture Media, Conditioned, Vascular Cell Adhesion Molecule-1, NADPH Oxidases, Pericytes, Matrix Metalloproteinase 2, Cell Proliferation, Receptors, Scavenger, Cyclooxygenase 2, Smad2 Protein, Interleukin-1beta, Transforming Growth Factor beta1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: TGF-beta1 regulates human brain pericyte inflammatory processes involved in neurovasculature function. https://app.cochat.ai/papers/10.1186/s12974-016-0503-0
The paper
Rustenhoven, J., Aalderink, M., Scotter, E. L., Oldfield, R. L., Bergin, P. S., Mee, E. W., Graham, E. S., Faull, R. L. M., Curtis, M. A., Park, T. I.-H., & Dragunow, M. (2016). TGF-beta1 regulates human brain pericyte inflammatory processes involved in neurovasculature function. Journal of Neuroinflammation. https://doi.org/10.1186/s12974-016-0503-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.